Login

Journal Front Page

News & Events

  • Call for article for January 2025 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 December, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • October 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 4 (October 2024 Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

Formulation and Evaluation of Colon Targeted Drug Delivery System of Budesonide Using Xylan as a Carrier

Subhendu S. Mishra*, Rajesh Ku. Nayak, S.N. Das

Gayatri College of Pharmacy, Gayatri Vihar, Jamadarpali, Sambalpur, Odisha.

ABSTRACT

Budesonide has been identified as a potential candidate to treat cancer particularly colorectal cancer. High dose is required in order to make sufficient quantity available at the desired site to elicit therapeutic response. Budesonide gets absorbed in upper part of intestine making its availability in the colon extremely low. Colon targeting approach with xylan matrix tablet of Budesonide hold tremendous potential for treatment of colon cancer. In the present research work, to prepared colon targeted matrix tablet investigate the release profile of budesonide from xylan based matrix tablets and attempts were also made to explore the feasibility of xanthan gum, guar gum and pectin as colon specific carrier for budesonide. The matix tablet was prepared four different formulations with different percentage of xylan. After evaluation of physical properties of tablet, the in vitro release study was performed in 0.1 N HCl pH 1.2 for 2 hrs, the dissolution medium was replaced with pH 7.4 for 3 hrs and then replaced with phosphate buffer pH 6.8 next 19 hrs. the in-vitro dissolution studies it was found to be that formulation F1 with 10% Xylan, F2 with 20% Xylan, F3 with 30% Xylan and F4 with 40 % Xylan all retard drug release in the stomach and small intestine effectively. F1 Xylan (10%) & F3 Xylan (30%) emerged to be best because it exhibits the best overall general appearance, hardness of 6.2 ± 0.498Kg/cm2, friability of 0.19802%, percentage drug released 53.51 ± 0.850 & hardness of 5.9 ± 0.124Kg/cm2, friability of 0.2004%, percentage drug released 42.75 ± 0.106 without rat caecal content at the end of 24 h invitro dissolution studies respectively. the matrix formulation containing 10% Xylan and 30% xylan is most like to target budesonide to colon without being release significantly in stomach & small intestine.

Keywords: Colon Targeted drug delivery system, Budesonide, Xylan


[Full Text Article]